Fahd Amjad, MD
Neurology · Washington, DCNPI 1477703312
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,482,477 of the $2,015,840 with a category attached, or 73.5%. 41 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 52.5% of the total. Among neurology clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,519 payments — averaging $800.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1.1M
- Acadia Pharmaceuticals Inc$474K
- Neurocrine Biosciences, Inc.$134K
- AbbVie$88K
- Lundbeck LLC$75K
- Kyowa Kirin, Inc.$64K
- plus $122K from 35 others
Across 127 payments — averaging $7218.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$885K
- Teva Pharmaceuticals USA, Inc.$32K
What the payments were for
- Consulting fees$196,38510%
- Speaking & faculty fees$1,482,47774%
- Travel & lodging$285,73914%
- Food & beverage$48,7472%
- Education$2,4920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,015,840 in reported general payments places this provider in the 95th percentile of 113 neurology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 181 | $1,318,955 |
| Droxidopa | 82 | $377,967 |
| RytaryCarbidopa/Levodopa | 191 | $318,713 |
| Austedo XrDeutetrabenazine | 43 | $291,035 |
| XenazineTetrabenazine | 12 | $269,597 |
| NourianzIstradefylline | 91 | $244,403 |
| IngrezzaValbenazine Tosylate | 21 | $176,202 |
| OngentysOpicapone | 89 | $123,362 |
| GocovriAmantadine Hcl | 35 | $114,746 |
| AustedoDeutetrabenazine | 30 | $87,567 |
| NeuproRotigotine | 38 | $57,331 |
| InbrijaLevodopa | 23 | $39,778 |
| Rasagiline Mesylate | 167 | $29,254 |
| Rivastigmine | 120 | $27,880 |
| XeominIncobotulinumtoxina | 18 | $23,652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $474,291 | $1,318,955181 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $1,058,631 | $378,60273 claims |
| Amneal Pharmaceuticals LLCRytary | $55,239 | $318,713191 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $133,586 | $299,564110 claims |
| Lundbeck LLCXenazine | $74,924 | $269,59712 claims |
| Kyowa Kirin, Inc.Nourianz | $64,080 | $244,40391 claims |
| MDD US Operations, LLCGocovri | $14,711 | $114,74635 claims |
| UCB, Inc.Neupro | $9,425 | $57,33138 claims |
| Acorda Therapeutics, IncInbrija | $93 | $39,77823 claims |
| Merz North America, Inc.Xeomin | $411 | $23,65218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 113 neurology providers in District of Columbia.
Other neurology in Washington
- Laxman BahrooWashington$3.1M
- Jessica AilaniWashington$1.2M
- Yasar Torres-YaghiWashington$969K
- Benjamin OsborneWashington$747K
- Fernando PaganWashington$690K
- Faria AmjadWashington$557K
- Brian BarryWashington$359K
- Carrie DoughertyWashington$327K
- Carlo TornatoreWashington$318K
- Tricia TingWashington$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.